Healthpoint, DFB to pay up to $48M in drug case

(AP)—Healthpoint Ltd. and DFB Pharmaceuticals will pay up to $48 million to settle allegations that Healthpoint marketed a prescription skin ointment without approval from federal regulators.

The Justice Department said Healthpoint caused false claims for reimbursement to be submitted to Medicare and Medicaid for Xenaderm, which is used for treating nursing home patients' bed sores. Fort Worth, Texas-based Healthpoint is one of DFB's operating companies.

The government alleged that Healthpoint's business strategy was to market new modeled after products that were available before October 1962 in order to avoid the time, effort and expense of obtaining approval from the . Products containing Xenaderm's principal were on the market before 1962, but the FDA determined the ingredient was less-than-effective for its intended use.

not rated yet
add to favorites email to friend print save as pdf

Related Stories

Novo Nordisk pays $26.7 million to settle claims

Jun 11, 2011

Danish drug company Novo Nordisk has agreed to pay $25 million to settle allegations that it promoted the misuse of blood clotting drug NovoSeven, the US Justice Department announced Friday.

FDA cracks down on untested cold medicines

Mar 02, 2011

(AP) -- The Food and Drug Administration says it will remove roughly 500 unapproved cold and allergy medications from the market as part of an ongoing campaign cracking down on ineffective prescription medications.

FDA orders lower doses in prescription painkillers

Jan 13, 2011

(AP) -- Federal health regulators are limiting a key ingredient found in Vicodin, Percocet and other prescription painkillers that have been linked to thousands of cases of liver damage each year.

FDA concerned about some STD medications

Mar 10, 2008

The U.S. Food and Drug Administration has warned six companies to stop marketing unapproved drugs for treating and preventing sexually transmitted diseases.

Recommended for you

WHO: Millions of Ebola vaccine doses ready in 2015

15 hours ago

The World Health Organization says millions of doses of two experimental Ebola vaccines could be ready for use in 2015 and five more experimental vaccines will start being tested in March.

Added benefit of vedolizumab is not proven

Oct 23, 2014

Vedolizumab (trade name Entyvio) has been approved since May 2014 for patients with moderately to severely active Crohn disease or ulcerative colitis. In an early benefit assessment pursuant to the Act on the Reform of the ...

Seaweed menace may yield new medicines

Oct 22, 2014

An invasive seaweed clogging up British coasts could be a blessing in disguise. University of Greenwich scientists have won a cash award to turn it into valuable compounds which can lead to new, life-saving drugs.

User comments